WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

2024.02.13
The 2023 World Conference on Lung Cancer (WCLC), held from September 9th to 12th at the Singapore, provided a platform for oncology experts to delve into cutting-edge developments. The “Oncology Frontier” team reports on-the-spot international cutting-edge developments and witnesses the progress of China's anti-cancer cause on the international stage. Renowned oncologist Dr. Baohui Han, from the Shanghai Chest Hospital, delivered a significant address at the conference. In an exclusive interview with “Oncology Frontier”, Dr. Han shared profound insights into the latest breakthroughs and contemplations on hot topics in targeted therapy for lung cancer.
WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

2024.02.13
The 2023 World Conference of Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was grandly held in Singapore from September 9th to 12th. At the WCLC conference, Dr. Clarissa Baldotto, President of the Brazilian Group of Thoracic Oncology, was invited by “Oncology frontier” to talk about the treatment strategies for lung cancer after immunotherapy failure, as well as the current status and future development of oncology in Brazil.
Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study

Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study

2024.02.13
The 24th World Conference on Lung Cancer (WCLC) was held from September 9 to 12, 2023, in Singapore, organized by the International Association for the Study of Lung Cancer (IASLC). During the oral presentation session on September 10, the EVOKE-02 study, exploring the first-line treatment of advanced non-small cell lung cancer (NSCLC) with the combination of sacituzumab govitecan (SG) and pembrolizumab, revealed its preliminary results. The study demonstrated an objective response rate (ORR) of 56% and a disease control rate (DCR) of 82% for stage IV NSCLC patients, laying the foundation for a new treatment strategy. " Oncology Frontier" invited Dr. Stephen V. Liu from Georgetown University Lombardi Comprehensive Cancer Center and Dr. Shun Lu from Shanghai Chest Hospital and Shanghai Jiao Tong University for a virtual dialogue to discuss the significance of the EVOKE-02 study and the future possibilities in NSCLC treatment.